Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

9/433 Matches for
“metabolic dysfunction-associated steatotic liver disease”

“metabolic dysfunction-associated steatotic liver disease” Clear all

  1. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 100

    …between heart disease and metabolic-dysfunction-associated steatotic liver disease (MASLD); however…

    FibroTest Metabolic

  2. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 95

    …arterial calcification and metabolic dysfunction-associated steatotic liver disease (MASLD) are linked…

    ActiTest FibroTest NashTest SteatoTest +1

  3. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 89

    …liver severity in people with metabolic dysfunction-associated steatotic liver disease (MASLD…

    FibroTest Metabolic

  4. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 84

    …tests in patients with metabolic liver disease (MASLD). An unmet need is…

    FibroTest-T2D Metabolic

  5. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025 Match 78

    …Assessing liver fibrosis is crucial for managing autoimmune hepatitis (AIH), yet reliance…

    ActiTest FibroTest AIH

  6. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 73

    …fatty liver disease (NAFLD) on the other hand are strongly associated with…

    ActiTest FibroTest NashTest SteatoTest +1

  7. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 67

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  8. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 62

    …rare metabolic disease with a larger impact than liver disease. Our work…

    FibroTest Metabolic

  9. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 56

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

Showing the full result list. The page is server-rendered and not paginated.